Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 26, 2017
Pharmacy Choice - Pharmaceutical News - Dr. Reddy's To Launch Generic Version Of Doxil - September 26, 2017

Pharmacy News Article

 5/17/17 - Dr. Reddy's To Launch Generic Version Of Doxil

NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY) announced it has received approval from the U.S. FDA to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil (doxorubicin hydrochloride liposome injection), for intravenous use, in the U.S. market.

The Doxil brand and generic had U.S. sales of approximately $196 million MAT for the most recent twelve months ending in March 2017. DOXIL is a registered trademark of ALZA Corp.

Dr. Reddy's Laboratories stated that the FDA approval is an outcome of extensive collaboration with the company's partner, Natco Pharma Ltd. on R&D and manufacturing capabilities.



Copyright RTT News/dpa-AFX

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Sep 26: Vitamins, Minerals, and Electrolytes in Older Adults
Last Chance
Sep 27: Medication Use During Pregnancy & Lactation
Sep 28: An Integrative Approach to Managing Arthritis
Sep 29: Legal & Practical Issues in Compounding Pharmacy
Oct 02: Efficacy vs. Safety: Treating BPH & Incontinence in the Elderly
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415